Association between CD14 rs2569190 C>T polymorphism and ischemic stroke susceptibility: a meta-analysis based on 5,277 subjects
Authors Wu YQ, Cheng SY, Xu XC, Li WC
Received 25 August 2018
Accepted for publication 17 November 2018
Published 21 December 2018 Volume 2019:15 Pages 47—55
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yuping Ning
Yan-Qiong Wu,1,* Shi-Yan Cheng,2,* Xian-Cheng Xu,1 Wen-Cui Li3
1Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China; 2Department of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou 441300, China; 3Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
*These authors contributed equally to this work
Introduction: Previous epidemiological studies have suggested that CD14 rs2569190 C>T polymorphism plays an important role in ischemic stroke (IS) risk, but the results were inconsistent. Therefore, we conducted a meta-analysis to determine the association between CD14 rs2569190 C>T polymorphism and IS susceptibility.
Methods: Online databases were searched from inception up to July 1, 2018, for studies concerning CD14 rs2569190 C>T polymorphism and its association with IS susceptibility. ORs and corresponding 95% CIs were calculated in the genetic models of each polymorphism locus with Stata Version 14.0. Furthermore, heterogeneity, meta-regression, accumulative analyses, sensitivity analyses, and publication bias were examined.
Results: Overall, 10 observed studies involving 5,277 subjects were included in this meta-analysis on CD14 rs2569190 C>T polymorphism. Generally, no significant associations were found between CD14 rs2569190 C>T polymorphism and IS risk (allele contrast of T vs C: OR =1.03, 95% CI =0.96–1.12, P=0.41, I2=27.8%; co-dominant models of CT vs CC: OR =1.01, 95% CI =0.81–1.25, P=0.95, I2=51.9%; co-dominant models of TT vs CC: OR =1.04, 95% CI =0.89–1.22, P=0.62, I2=25.1%; dominant model of CT + TT vs CC: OR =1.02, 95% CI =0.84–1.25, P=0.82, I2=51.4%; recessive model of TT vs CC + CT: OR =1.07, 95% CI =0.95–1.22, P=0.28, I2=0%), similar to the results in the subgroup analysis.
Conclusion: The current evidence indicated that CD14 rs2569190 C>T polymorphism was not a critical risk factor for IS development.
Keywords: CD14, ischemic stroke, polymorphism
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]